DNAJA2 and plasma cell myeloma: Consistent with these results, analysis of cancer database48 revealed that cancer patients with a lower level of DNAJA2 (DNAJA2-low) displayed a better surviving rate than those with a higher level of DNAJA2 (DNAJA2-high) in several types of cancers analyzed, including lung and breast cancers (Fig. 7g), as well as colorectal cancers, neuroblastoma and myeloma (Supplementary Fig. 7b).